[go: up one dir, main page]

CR7952A - Sistema terapeutico transdermico estable a los rayos uv - Google Patents

Sistema terapeutico transdermico estable a los rayos uv

Info

Publication number
CR7952A
CR7952A CR7952A CR7952A CR7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A
Authority
CR
Costa Rica
Prior art keywords
rays
active substance
absorbing agent
therapeutic system
transdermal therapeutic
Prior art date
Application number
CR7952A
Other languages
English (en)
Inventor
Schumacher Jochen
Susse Manfred
Mletzko Stephan
Ingwersen Jan-Peter
Langguth Thomas
Schenk Dirk
Kaffl Hubert
Dittgen Michael
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR7952A publication Critical patent/CR7952A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El invento se refiere a un nuevo sistema terapeutico transdermico estable a los rayos UV (TTS) que consiste en una capa de base, por lo menos una matriz que contiene sustancia activa y opcionalmente una pelicula despegable y ademas un agente absorbedor de rayos UV, donde entre la capa de base y la matriz que contiene sustancia activa, que se encuentra mas alejada de la superficie de la piel, se preve por lo menos una capa adhesiva que contiene agente absorbedor de rayos UV y entre la capa adhesiva que contiene el agente absorbedor de rayos UV y la matriz que contiene sustancia activa, que estÓ mas alejada de la superficie de la piel, se preve por lo menos una capa separadora que es impermeable a la sustancia activa e impermeable al agente absorbedor de rayos UV.
CR7952A 2003-02-21 2005-08-19 Sistema terapeutico transdermico estable a los rayos uv CR7952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster

Publications (1)

Publication Number Publication Date
CR7952A true CR7952A (es) 2006-02-06

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7952A CR7952A (es) 2003-02-21 2005-08-19 Sistema terapeutico transdermico estable a los rayos uv

Country Status (30)

Country Link
US (3) US8486443B2 (es)
EP (1) EP1594483B1 (es)
JP (1) JP4528296B2 (es)
KR (1) KR100704825B1 (es)
AR (1) AR043248A1 (es)
AT (1) ATE333271T1 (es)
AU (1) AU2004212675B2 (es)
BR (1) BRPI0407615B8 (es)
CA (1) CA2515918C (es)
CR (1) CR7952A (es)
CY (1) CY1105716T1 (es)
DE (1) DE502004000988D1 (es)
DK (1) DK1594483T3 (es)
EA (1) EA008098B1 (es)
EC (1) ECSP056030A (es)
ES (1) ES2270345T3 (es)
HR (1) HRP20050828B1 (es)
IL (1) IL170295A (es)
IS (1) IS2541B (es)
ME (2) MEP14008A (es)
MX (1) MXPA05008778A (es)
NO (1) NO336108B1 (es)
NZ (1) NZ541807A (es)
PE (1) PE20041028A1 (es)
PL (1) PL219030B1 (es)
PT (1) PT1594483E (es)
RS (1) RS50428B (es)
SI (1) SI1594483T1 (es)
UY (1) UY28189A1 (es)
WO (1) WO2004073696A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CN101005833A (zh) * 2004-08-20 2007-07-25 3M创新有限公司 具有半透明保护膜的透皮药物递送装置
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
WO2010009122A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
EP2613772B1 (en) * 2010-09-06 2016-12-14 Bayer Intellectual Property GmbH Low-dose transdermal patches with high drug release
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018008190A (es) 2015-12-30 2018-11-12 Corium Int Inc Sistemas y metodos para la administracion transdermica a largo plazo.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (es) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
ES2081823T3 (es) 1988-10-27 1996-03-16 Schering Ag Agente para la aplicacion transdermica, que contiene gestoden.
DE59107052D1 (de) 1990-03-30 1996-01-25 Ciba Geigy Ag Lackzusammensetzungen
EP0483370B1 (en) 1990-05-17 1995-03-29 Hisamitsu Pharmaceutical Co., Inc. Percutaneous preparation containing estradiol
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
PT99338A (pt) 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
WO1996015776A1 (en) 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP3908795B2 (ja) 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
AU703593B2 (en) 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
EP0976405A4 (en) 1997-04-16 2000-12-06 Hisamitsu Pharmaceutical Co BASIC COMPOSITION FOR PERCUTANE ABSORPTION AND PERCUTANE ABSORBABLE PREPARATION THAT CONTAINS BASIC COMPOSITION
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
WO2000045798A1 (en) 1999-02-02 2000-08-10 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
WO2001001990A1 (en) 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
PT1242012E (pt) 1999-11-24 2010-03-31 Agile Therapeutics Inc Sistema e processo melhorado de libertação transdérmica de contraceptivo
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
WO2001068061A1 (en) 2000-03-17 2001-09-20 Hisamitsu Pharmaceutical Co., Inc. Ultraviolet-shielding adhesive preparation
JP5038576B2 (ja) * 2000-06-13 2012-10-03 久光製薬株式会社 貼付剤
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
WO2002045701A2 (en) 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
CA2478206A1 (en) 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
US7387753B2 (en) 2003-08-25 2008-06-17 Bfs Diversified Products, Llc Method and apparatus to monitor the compressive strength of insulation boards
AU2004270402A1 (en) 2003-09-11 2005-03-17 Ciba Specialty Chemicals Holding Inc. Water based concentrated product forms of light stabilizers made by a heterophase polymerization technique
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
NZ548091A (en) 2003-12-12 2009-12-24 Bayer Schering Pharma Ag Transdermal delivery system of hormones without penetration enhancers
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP2742934A1 (en) 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
NO336108B1 (no) 2015-05-18
US8486443B2 (en) 2013-07-16
PL378035A1 (pl) 2006-02-20
AU2004212675B2 (en) 2006-06-01
PT1594483E (pt) 2006-12-29
JP2006518348A (ja) 2006-08-10
RS50428B (sr) 2009-12-31
HRP20050828B1 (hr) 2013-10-25
DE502004000988D1 (de) 2006-08-31
US20130226113A1 (en) 2013-08-29
IS8031A (is) 2005-09-15
ME00147B (me) 2010-10-10
EP1594483A1 (de) 2005-11-16
EA200501224A1 (ru) 2006-04-28
IS2541B (is) 2009-09-15
ECSP056030A (es) 2006-01-27
BRPI0407615A (pt) 2006-02-14
ATE333271T1 (de) 2006-08-15
AU2004212675A1 (en) 2004-09-02
ES2270345T3 (es) 2007-04-01
EP1594483B1 (de) 2006-07-19
SI1594483T1 (sl) 2006-12-31
IL170295A (en) 2010-05-31
CA2515918C (en) 2010-11-16
PE20041028A1 (es) 2005-02-18
US20060251707A1 (en) 2006-11-09
MXPA05008778A (es) 2006-05-25
KR100704825B1 (ko) 2007-04-09
MEP14008A (en) 2010-06-10
US9095691B2 (en) 2015-08-04
NO20054321L (no) 2005-09-20
PL219030B1 (pl) 2015-03-31
US20150335658A1 (en) 2015-11-26
DK1594483T3 (da) 2006-11-20
RS20050639A (sr) 2007-09-21
KR20050103499A (ko) 2005-10-31
CY1105716T1 (el) 2010-12-22
EA008098B1 (ru) 2007-02-27
BRPI0407615B1 (pt) 2018-02-14
BRPI0407615B8 (pt) 2021-05-25
AR043248A1 (es) 2005-07-20
WO2004073696A1 (de) 2004-09-02
HRP20050828A2 (en) 2006-03-31
UY28189A1 (es) 2004-04-30
CA2515918A1 (en) 2004-09-02
NZ541807A (en) 2009-07-31
JP4528296B2 (ja) 2010-08-18
HK1085394A1 (zh) 2006-08-25

Similar Documents

Publication Publication Date Title
CR7952A (es) Sistema terapeutico transdermico estable a los rayos uv
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
CL2003002767A1 (es) Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral.
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
AR097045A2 (es) Sistema terapéutico transdérmico
DE50112720D1 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
PT1339397E (pt) Camada de cobertura impermeavel a substancias activas e contendo agentes absorventes e formadores de canais ou camada protectora amovivel de um sistema terapeutico transdermico
DOP2006000168A (es) Dispositivos transdérmicos de liberación de fármaco que contienen drospirenona y métodos de liberación de los mismos
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
AR029227A1 (es) Estructura compuesta de una matriz adhesiva que contiene una o varias substancias activas;procedimiento para fabricar una estructura compuesta, uso de estructuras compuestas y apilamiento de dichas estructuras compuestas.
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
SE0300960D0 (sv) Material for packaging purposes
ES2523663T3 (es) Sistema terapéutico transdérmico sólido con un agente absorbente de los rayos UV
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
ECSP066689A (es) Forma de administración transdérmica, líquida o semisólida que contiene sustancia activa sensible a la luz, estable a los rayos ultravioletas
AR022956A1 (es) Sistema transdermal terapeutico y procedimiento para su fabricacion
AR029718A1 (es) Composicion farmaceutica a base de cocaetileno y su utilizacion para el tratamiento de la dependencia de las substancias psicoactivas
GT200600469A (es) Dispositivos de administración transdermica de drogas que contienen drospirenona y metodos de administración de la misma.
CO5550461A2 (es) Tratamiento de enfermedad parasitaria